800-331-6634

Research

Recruiting

Macular Degeneration

Wet AMD

  • OPH1002 Sponsored by Ophthotech Corporation
    A Phase 3 Safety and Efficacy Study of Fovista™ (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

 

  • PAN-01-101 Sponsored by Pan Optica, Inc
    Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

 

  • ATLAS. Sponsored by Wills Eye Institute.
    Optical coherence tomography guided treat and extend therapy for neovascular age related macular degeneration using aflibercept.

Dry AMD

  • ACT MA09-hRPE-AMD-001 Sponsored by Advanced Cell Technology Inc.
    A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine  the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic  Stem Cell Derived Retinal Pigmented Epithelial (MA 09-hRPE) Cells in Patients  with Advanced Age-related Macular Degeneration (AMD).

Stargardts

 

  • ACT MA09-hRPE-SMD-001 Sponsored by Advanced Cell Technology Inc.
    A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA 09-hRPE) Cells in Patients with Stargardt’s Macular Dystrophy (SMD).

 

Uveitis

 

  • EYEGUARD Sponsored by Xoma (US) LLC
    Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment (EYEGUARD™-C)

 

  • 32-007 Sponsored by Santen Inc.
    A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye

Retinal Detachment

  • AVASTIN PVR Sponsored by Wills Eye
  • Injections of Bevacizumab to See if Medication Helps to Lower Risk of Scar Tissue Development in the Retina and Repeated Retinal Detachment.

CSR

  • ECSelsior Sponsored by Wills Eye
    Eplerenone for the Treatment of Central Serous Chorioretinopathy

CRVO or BRVO

  • DRIVEN Sponsored by Allergan
    Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion